Report      Database

    Global Prostate Cancer Therapeutics Market to 2020

    Date: 06 Nov, 2015              Type: PDF              Pages: 80

    Global Prostate Cancer Therapeutics Market to 2020
    • Electronic Access - Single User License
      $1,200.00
    • CD-ROM Mail Delivery
      $1,300.00
    • Hard-copy Mail Delivery
      $1,300.00
    • Electronic Access - Multi User License
      $1,800.00

    Global Prostate Cancer Therapeutics Market Overview

    The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone–refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future.
     

    Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer's cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.

    Renub Research report titled “Global Prostate Cancer Therapeutics Market to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.

    The report covers the following:
     

    1. Global Prostate Cancer – Hormonal Therapy Drugs Market

    •  Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists

    1. Zytiga
    2. Gonax


    •  Luteinizing Hormone–Releasing Hormone (LHRH) Analogs

    1. Lupron
    2. Zoladex
    3. Decapeptyl
    4. Eligard
    5. Vantas
    6. Leuplin

    •  Anti–Androgens  
    1. Casodex
    2. Xtandi or MDV3100
    3. Xtandi US or MDV3100


    2. Global Prostate Cancer Chemotherapy Drugs Market

    1. Taxotere
    2. Jevtana


    3. Global Prostate Cancer Immunotherapy Drugs Market

    1. Provenge


    4. Global Prostate Cancer Targeted Therapy Drugs Market

    1. Xofigo or Alpharadin
     

     

    Press Release: Advances in medical science promises new drugs for Prostate Cancer

     

    What is a Prostate Cancer?

    Prostate cancer is an evolution of cancer in the prostate, a gland present in the male reproductive system which exists directly under the bladder in front of the rectum. The cancer cells may extend from the prostate to the other parts of the body, i.e. the lymph nodes and the bones. Soon after next levels of cancer, it can cause blood in the urine, trouble in urination, etc. Family history, race and Old age are the factors that add to the risk of prostate cancer. The prostate creates the liquid that sustains sperm on their excursion to combine with a female ovum, or egg, and deliver human life. The prostate powers and gets these liquids out in sexual climax.

    By the year 2020, the prostate cancer drugs market is projected to reach nearly two folds from the current market due to the introduction of new as well as expensive drugs. Therapeutics companies have long expected successfully launching new drugs to drive the market. This pressure is only likely to enhance. Product channels are decreasing and patents are expiring. Severity measures in numerous nations are growing national and local challenges for market access. At once launches of drugs are becoming more competitive, more numerous, and as well as smaller.

    Still, their current track record is sobering at best. Around two-thirds of new drugs fall short to meet prelaunch accord sales prospects for their first year on the market, and those that fails usually continue to under deliver for the coming years. Each launch of the drugs has its own set of triumph. 

    Approximately one in four launches engage drugs that are strongly differentiated from competing products and treat diseases with a high perceived burden. Examples like Zytiga, Johnson & Johnson’s drugs for prostate-cancer treatment. These drugs launches run a significant risk of companies believing that the product’s high quality guarantees high sales volume. 


    Italian study asserts

    A new Italian study asserts that drinking three or more cups of caffeinated coffee a day may diminish the risk of prostate cancer about 50 percent. It also sheds light on the role of coffee prepared the Italian, and specifically caffeine, in relation to prostate cancer. Italians prepare their coffee thoroughly, with very high water temperature, under high pressure, and without filters.
     

    Global Prostate cancer drugs in the market 

    The introduction of premium priced therapies for the cure of prostate cancer. Renub Research predicts that the launch of drugs for the treatment of localized prostate cancer and castration-resistant prostate cancer (CRPC). Xtandi, Gonax, Zytiga, Lupron and Taxotere etc drugs are helpful in the treatment of hormone sensitive’s prostate cancer. Decapeptyl, Taxotere, Jevtana and Provenge are some other popular prostate cancer drugs in the market globally.


    Key Segments Outlook

    By therapy type, the market has been classified into chemotherapy, hormone therapy targeted therapy and Immuno therapy. The market segments have been analyzed based on cost-effectiveness, accessible approved products, and inclination from oncologists for treating the prostate cancer with numerous drugs. The market size and forecast for each of these segments have been provided for the period from 2015 to 2020.

    By distribution channels, the global prostate cancer therapeutics market has been classified into retail pharmacy, online sales, hospital pharmacy and others. The market segments have been comprehensively analyzed on rising in demand for disease treatment among prostate cancer patients. Hospital pharmacy drives the market share due to increased patient hospitalizations for the treatment of prostate cancer. 


    Regional Outlook 

    The growing diseased population and a revolutionary healthcare infrastructure will support the expansion of the prostate cancer therapeutics market in North America and Europe. Apart from that Asia Pacific is likely to emerge as the promising market. The expanding healthcare spending will also support the market’s growth in Asia Pacific.
     

     

    Data Sources
     
    This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
     

    Primary sources include industry surveys and telephone interviews with industry experts.
     

    Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

    1. Executive Summary

    2. Prostate Cancer – Overview
    2.1 Prostate Cancer Introduction
    2.2 Risk Factors
    2.2.1 Age
    2.2.2 Race
    2.2.3 Family History/Genetics
    2.2.4 Diet/Lifestyle Factors
    2.2.5 Obesity
    2.2.6 Infection/Inflammation of the Prostate Gland
    2.3 Disease Symptoms
    2.4 Diagnosis
    2.4.1 Digital Rectal Exam (DRE)
    2.4.2 Prostate Specific Antigen (PSA) Blood Test
    2.4.3 Prostate Ultrasound and Biopsy
    2.4.4 Bone Scan
    2.4.5 CT Scan & MRI
    2.4.6 PET & SPECT Scan
    2.4.7 Lymph Node Biopsy
    2.4.8 ProstaScint Scan
    2.5 Stages of Prostate Cancer
    2.5.1 Stage I
    2.5.2 Stage II
    2.5.3 Stage III
    2.5.4 Stage IV

    3. Global Prostate Cancer Drugs Market

    4. Global Prostate Cancer Incidence

    5. Global Prostate Cancer Drugs Market Share

    6. Global Prostate Cancer – Hormonal Therapy Drugs Sales & Forecast to 2020
    6.1 Luteinizing Hormone – Releasing Hormone (LHRH) Antagonists
    6.1.1 Zytiga
    6.1.2 Gonax / Firmagon
    6.2 Luteinizing Hormone – Releasing Hormone (LHRH) Analogs
    6.2.1 Lupron
    6.2.2 Zoladex
    6.2.3 Decapeptyl
    6.2.4 Eligard
    6.2.5 Vantas
    6.2.6 Leuplin
    6.3 Anti – Androgens
    6.3.1 Casodex
    6.3.2 Xtandi or MDV3100
    6.3.3 Xtandi US or MDV3100

    7. Global Prostate Cancer – Chemotherapy Drugs Market
    7.1 Taxotere
    7.2 Jevtana

    8. Global Prostate Cancer – Immunotherapy Drugs Market
    8.1 Provenge

    9. Global Prostate Cancer – Targeted Therapy Drugs Market
    9.1 Xofigo or Alpharadin

    10. Global Prostate Cancer Market – Driving Factors
    10.1 Introduction of Innovative Drugs
    10.2 Advancement in Oncology Therapeutic Area
    10.3 Development in Genomics & Proteomics

    11. Global Prostate Cancer Market – Challenges
    11.1 Costly Prostate Cancer Drugs
    11.2 Adverse Events of Treatment
    11.3 Low Success Rate for Oncology Drugs

     

    List of Figures:

    Figure 3–1: Global – Prostate Cancer Drugs Market (Million US$), 2010 – 2014
    Figure 3–2: Global – Forecast for Prostate Cancer Drugs Market (Million US$), 2015 – 2020

    Figure 4–1: Global – Prostate Cancer Incidence (Number), 2007 – 2014
    Figure 4–2: Global – Forecast for Prostate Cancer Incidence (Number), 2015 – 2020

    Figure 6–1: Global – Zytiga Drugs Sales (Million US$), 2011 – 2014
    Figure 6–2: Global – Forecast for Zytiga Drugs Sales (Million US$), 2015 – 2020
    Figure 6–3: Global – Gonax/ Firmagon Drugs Sales (Million US$), 2012 – 2014
    Figure 6–4: Global – Forecast for Gonax Drugs Sales (Million US$), 2015 – 2020
    Figure 6–5: Global – Lupron Drugs Sales (Million US$), 2009 – 2014
    Figure 6–6: Global – Forecast for Lupron Drugs Sales (Million US$), 2015 – 2020
    Figure 6–7: Global – Zoladex Drugs Sales (Million US$), 2009 – 2014
    Figure 6–8: Global – Forecast for Zoladex Drugs Sales (Million US$), 2015 – 2020
    Figure 6–9: Global – Decapeptyl Drugs Sales (Million US$), 2009 – 2014
    Figure 6–10: Global – Forecast for Decapeptyl Drugs Sales (Million US$), 2015 – 2020
    Figure 6–11: Global – Eligard Drug Sales (Million US$), 2009 – 2014
    Figure 6–12: Global – Forecast for Eligard Drug Sales (Million US$), 2015 – 2020
    Figure 6–13: Global – Vantas Drugs Sales (Million US$), 2009 – 2014
    Figure 6–14: Global – Forecast for Vantas Drugs Sales (Million US$), 2015 – 2020
    Figure 6–15: Global – Leuplin Drugs Sales (Million US$), 2009 – 2014
    Figure 6–16: Global – Forecast for Leuplin Drugs Sales (Million US$), 2015 – 2020
    Figure 6–17: Global – Casodex Drug Sales (Million US$), 2009 – 2014
    Figure 6–18: Global – Forecast for Casodex Drug Sales (Million US$), 2015 – 2020
    Figure 6–19: Global – Xtandi or MDV3100 Drug Sales (Million US$), 2012 – 2014
    Figure 6–20: Global – Forecast for Xtandi or MDV3100 Drug Sales (Million US$), 2015 – 2020
    Figure 6–21: Global – Xtandi US or MDV3100 Drug Sales (Million US$), 2012 – 2014
    Figure 6–22: Global – Forecast for Xtandi US or MDV3100 Drug Sales (Million US$), 2015 – 2020

    Figure 7–1: Global – Taxotere Drug Sales (Million US$), 2011 – 2014
    Figure 7–2: Global – Forecast for Taxotere Drug Sales (Million US$), 2015 – 2020
    Figure 7–3: Global – Jevtana Drug Sales (Million US$), 2010 – 2014
    Figure 7–4: Global – Forecast for Jevtana Drug Sales (Million US$), 2015 – 2020

    Figure 8–1: Global – Provenge Drugs Sales (Million US$), 2011 – 2014
    Figure 8–2: Global – Forecast for Provenge Drugs Sales (Million US$), 2015 – 2020

    Figure 9–1: Global – Xofigo or Alpharadin Drug Sales (Million US$), 2013 – 2014
    Figure 9–2: Global – Forecast for Xofigo or Alpharadin Drug Sales (Million US$), 2015 – 2020

    Figure 11–1: Therapeutic Categories – Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 – 2010

     

    List of Tables:

    Table 5–1: Global – Prostate Cancer Drugs Market Share (Percent), 2011 – 2014
    Table 5–2: Global – Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 – 2020

    • Description
      Price
    • Chapter 1 & 2     Pages : 15
      $150
    • Chapter 3     Pages : 2
      $200
    • Chapter 4     Pages : 2
      $200
    • Chapter 5     Pages : 4
      $250
    • Chapter 6     Pages : 21
      $390
    • Chapter 7     Pages : 4
      $100
    • Chapter 8     Pages : 3
      $50
    • Chapter 9     Pages : 2
      $50
    • Chapter 10     Pages : 6
      $100
    • Chapter 11     Pages : 5
      $100

    Related Products